We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
A recent guidance issued by the Centers for Medicare & Medicaid (CMS) has industry groups worrying whether reimbursements for their products could be cut -- or even eliminated.
Proponents of the Centers for Medicare & Medicaid Services’ (CMS) prescription drug plan and its detractors are engaging in a statistical battle to make their case for the impact of Part D on prescription drug prices, with industry groups and the agency pitted against consumer advocates.
Proponents of the Centers for Medicare & Medicaid Services’ (CMS) prescription drug plan and its detractors are engaging in a statistical battle to make their case for the impact of Part D on prescription drug prices, with industry groups and the agency pitted against consumer advocates.
The Centers for Medicare & Medicaid Services (CMS) is developing a regulation designed to ensure an accurate calculation of average manufacturer prices (AMPs) and will not post those prices by the required July 1 deadline, according to the head of the agency.
Nearly 70 percent of the Democrats in the House of Representatives have called on the head of the Centers for Medicare & Medicaid Services (CMS) to proactively notify low-income seniors of the extra assistance available to them under Medicare Part D.
The Centers for Medicare & Medicaid Services (CMS) will soon issue a regulation designed to ensure an accurate calculation of average manufacturer prices (AMPs) and will not post those prices by the required July 1 deadline, according to the head of the agency.
A private company pressing a lawsuit alleging Abbott Laboratories defrauded the federal government by inflating its drug prices more than 1,000 percent got a heavyweight on its side with the U.S. Justice Department’s filing of its own complaint.
Faulty calculations by the Centers for Medicare & Medicaid Services (CMS) could cause HHS to incorrectly adjust provider reimbursements for some drugs covered under Medicare Part B, according to a recent report by HHS’ Office of the Inspector General (OIG).
GlaxoSmithKline (GSK) will implement a plan that will allow people enrolled in the Medicare Part D program to reapply to GSK’s patient assistance program for transitional assistance through the end of the year.